Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus
Public ClinicalTrials.gov record NCT02052739. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and tolerability of SAGE-547 in participants in super-refractory status epilepticus (SRSE).
Study identification
- NCT ID
- NCT02052739
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 25 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 2 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 21, 2014 (Actual)
- Primary completion
- May 3, 2015 (Actual)
- Completion
- May 3, 2015 (Actual)
- Last update posted
- Sep 15, 2025
2014 – 2015
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sage Investigational Site | Birmingham | Alabama | 35294 | — |
| Sage Investigational Site | Sarasota | Florida | 34239 | — |
| Sage Investigational Site | Chicago | Illinois | 60611 | — |
| Sage Investigational Site | Wichita | Kansas | 67214 | — |
| Sage Investigational Site | New Orleans | Louisiana | 70121 | — |
| Sage Investigational Site | Boston | Massachusetts | 02114 | — |
| Sage Investigational Site | Boston | Massachusetts | 02115 | — |
| Sage Investigational Site | Ann Arbor | Michigan | 48109 | — |
| Sage Investigational Site | Detroit | Michigan | 48322 | — |
| Sage Investigational Site | New York | New York | 10032 | — |
| Sage Investigational Site | Rochester | New York | 14642 | — |
| Sage Investigational Site | Durham | North Carolina | 27710 | — |
| Sage Investigational Site | Winston-Salem | North Carolina | 27157 | — |
| Sage Investigational Site | Philadelphia | Pennsylvania | 19104 | — |
| Sage Investigational Site | Nashville | Tennessee | 37232 | — |
| Sage Investigational Site | Dallas | Texas | 75251 | — |
| Sage Investigational Site | Temple | Texas | 76504 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02052739, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 15, 2025 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02052739 live on ClinicalTrials.gov.